Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 8 von 633

Details

Autor(en) / Beteiligte
Titel
Engineered Staphylococcus auricularis Cas9 with high‐fidelity
Ist Teil von
  • The FASEB journal, 2023-08, Vol.37 (8), p.e23060-n/a
Ort / Verlag
United States
Erscheinungsjahr
2023
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
  • CRISPR‐Cas9 is a versatile gene editing tool with a broad application of basic research and clinical therapeutics. However, the potential impact caused by off‐target effects remains a critical bottleneck. The small Cas9 ortholog from Staphylococcus auricularis (SauriCas9) was identified, which recognizes a 5′‐NNGG‐3′ protospacer adjacent motif (PAM), exhibiting high activity for genome editing. Recently, we also reported enhanced‐fidelity Staphylococcus aureus Cas9 (efSaCas9), which harbors a single mutation N260D. Protein sequence alignment revealed that SauriCas9 has 62.4% sequence identity with SaCas9. Because SauriCas9 is more flexible in recognizing the target sequence with PAM of 5′‐NNGG‐3′ than SaCas9 of 5′‐NNGRRT‐3′ PAM, we sought to test whether key mutation(N260D) or adjacent residue mutation in efSaCas9 can be appliable to SauriCas9. With this concept, two engineered SauriCas9 variants (SauriCas9‐HF1, harboring the N269D mutation; SauriCas9‐HF2, harboring the D270N mutation) dramatically improved targeting specificity by targeted deep sequencing and GUIDE‐seq. At certain sites, reduced off‐target effects (approximately 61.6‐ and 111.9‐fold improvements) of SauriCas9‐HF2 compared with wild‐type SauriCas9 were observed. Overall, two identified SauriCas9 variants (SauriCas9‐HF1 and SauriCas9‐HF2) expand the utility of the CRISPR toolkit for research and therapeutic applications. Based on the key mutation of SaCas9 variant, we successfully generated two high‐fidelity variants of SauriCas9 (SauriCas9‐HF1 and SauriCas9‐HF2), which expand the utility of the CRISPR toolkit for research and therapeutic applications.
Sprache
Englisch
Identifikatoren
ISSN: 0892-6638
eISSN: 1530-6860
DOI: 10.1096/fj.202202132RR
Titel-ID: cdi_crossref_primary_10_1096_fj_202202132RR

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX